Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

AlphaRx Outsources Hepatitis Drug Manufacturing to Venturepharm

publication date: Dec 18, 2009
AlphaRx signed a long-term contract manufacturing agreement with Venturepharm. Under the agreement, Venturepharm will supply AlphaRx with the API for its experimental hepatitis drug ARX1088. ARX1088 is an oral interferon inducer that AlphRx is testing as an adjunct to standard interferon regimens. The company hopes to market the drug eventually in China and other emerging markets. Terms of the agreement were not disclosed. More details...

Stock Symbol: (OTCBB: ALRX)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital